- Home
- DNP vs GERN Comparison
DNP vs GERN Comparison
Compare DNP & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNP
- GERN
- Stock Information
- Founded
- DNP 1986
- GERN 1990
- Country
- DNP United States
- GERN United States
- Employees
- DNP N/A
- GERN N/A
- Industry
- DNP Investment Managers
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- DNP Finance
- GERN Health Care
- Exchange
- DNP Nasdaq
- GERN Nasdaq
- Market Cap
- DNP 3.1B
- GERN 2.5B
- IPO Year
- DNP N/A
- GERN 1996
- Fundamental
- Price
- DNP $9.69
- GERN $4.01
- Analyst Decision
- DNP
- GERN Strong Buy
- Analyst Count
- DNP 0
- GERN 9
- Target Price
- DNP N/A
- GERN $6.83
- AVG Volume (30 Days)
- DNP 708.8K
- GERN 7.4M
- Earning Date
- DNP 01-01-0001
- GERN 11-07-2024
- Dividend Yield
- DNP 8.63%
- GERN N/A
- EPS Growth
- DNP N/A
- GERN N/A
- EPS
- DNP N/A
- GERN N/A
- Revenue
- DNP N/A
- GERN $1,373,000.00
- Revenue This Year
- DNP N/A
- GERN $23,693.67
- Revenue Next Year
- DNP N/A
- GERN $401.91
- P/E Ratio
- DNP N/A
- GERN N/A
- Revenue Growth
- DNP N/A
- GERN 205.11
- 52 Week Low
- DNP $8.09
- GERN $1.64
- 52 Week High
- DNP $11.18
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- DNP 50.43
- GERN 39.33
- Support Level
- DNP $9.65
- GERN $4.11
- Resistance Level
- DNP $9.78
- GERN $4.37
- Average True Range (ATR)
- DNP 0.14
- GERN 0.17
- MACD
- DNP -0.02
- GERN -0.03
- Stochastic Oscillator
- DNP 54.31
- GERN 21.73
About DNP DNP Select Income Fund Inc.
DNP Select Income Fund Inc is a closed-ended investment management fund. The primary investment objectives of the fund are current income and long-term growth of income. Its secondary objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing in the public utility industry.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.